AI assistant
Sending…
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2023
Dec 12, 2023
31542_dirs_2023-12-12_6d5b22c4-00c4-42fd-8244-87bdd3df2abe.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2023-12-08
Reporting Person: O'Keeffe Charles B (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-12-08 | Options to purchase common stock | $14.15 | A | 29524 | Acquired | 2030-12-08 | Common Stock (29524) | Direct |
| 2023-12-08 | Restricted stock units | $ | A | 4240 | Acquired | Common Stock (4240) | Direct |
Footnotes
F1: Derivative securities vest in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025 and 1/3rd on December 8, 2026.
F2: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F3: Shares of common stock will be delivered to the Reporting Person upon vesting.
More from CATALYST PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 11
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Feb 25
Annual Report
2026
Feb 25
Director's Dealing
2026
Feb 19
Regulatory Filings
2026
Jan 12
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6
Director's Dealing
2025
Dec 30